Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 21

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 21
---
 changes in beliefs. In the event
that any forward-looking statement is updated, no inference should be made that we will make additional updates with respect to that statement,
related matters, or any other forward-looking statements. Any corrections or revisions and other important assumptions and factors that
could cause actual results to differ materially from forward-looking statements, including discussions of significant risk factors, may
appear in our public filings with the SEC, which are or will be (as appropriate) accessible at www.sec.gov, and which you are advised
to consult. For additional information, please see the section titled “Where You Can Find More Information; Incorporation of
Information by Reference” elsewhere in this prospectus supplement.

Market, ranking and industry data used throughout
this prospectus supplement, including statements regarding market size and technology adoption rates, is based on the good faith estimates
of our management, which in turn are based upon our management’s review of internal surveys, independent industry surveys and publications
including third party research and publicly available information. These data involve a number of assumptions and limitations, and you
are cautioned not to give undue weight to such estimates. While we are not aware of any misstatements regarding the industry data presented
herein, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under
the heading “Risk Factors” in this prospectus supplement and the accompanying base prospectus and in and “Risk Factors” and “Operating and Financial Review and Prospects” in our Annual Report.

<div align='center'>S-11

USE OF PROCEEDS</div>

We expect to receive net proceeds from this offering, after deducting
estimated offering expenses payable by us, of approximately $36.7 million.

We currently intend to use any net proceeds from this offering, together
with our existing cash and cash equivalents for general corporate purposes, including research and development related purposes in connection
with our product candidates and for potential commercialization of our product candidates.

This expected use of our net
proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the
future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending
on numerous factors. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to
estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. As such, our
management will retain broad discretion over